EP0481065A1 - Process for nucleic acid hybridization and amplification. - Google Patents
Process for nucleic acid hybridization and amplification.Info
- Publication number
- EP0481065A1 EP0481065A1 EP91910088A EP91910088A EP0481065A1 EP 0481065 A1 EP0481065 A1 EP 0481065A1 EP 91910088 A EP91910088 A EP 91910088A EP 91910088 A EP91910088 A EP 91910088A EP 0481065 A1 EP0481065 A1 EP 0481065A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- dna
- reca
- protein
- strand
- stranded
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 42
- 230000003321 amplification Effects 0.000 title claims abstract description 25
- 238000003199 nucleic acid amplification method Methods 0.000 title claims abstract description 25
- 230000008569 process Effects 0.000 title description 5
- 238000007899 nucleic acid hybridization Methods 0.000 title description 2
- 108010055016 Rec A Recombinases Proteins 0.000 claims abstract description 215
- 102000001218 Rec A Recombinases Human genes 0.000 claims abstract description 202
- 108020004414 DNA Proteins 0.000 claims abstract description 170
- 238000006243 chemical reaction Methods 0.000 claims abstract description 129
- 102000053602 DNA Human genes 0.000 claims abstract description 33
- 230000000295 complement effect Effects 0.000 claims abstract description 27
- 241000589500 Thermus aquaticus Species 0.000 claims abstract description 23
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims abstract description 19
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 230000000536 complexating effect Effects 0.000 claims abstract description 5
- 238000010494 dissociation reaction Methods 0.000 claims abstract description 4
- 230000005593 dissociations Effects 0.000 claims abstract description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 174
- 102000004169 proteins and genes Human genes 0.000 claims description 163
- 238000003786 synthesis reaction Methods 0.000 claims description 23
- 102000004594 DNA Polymerase I Human genes 0.000 claims description 20
- 108010017826 DNA Polymerase I Proteins 0.000 claims description 20
- 241000588724 Escherichia coli Species 0.000 claims description 19
- 239000011541 reaction mixture Substances 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 11
- 108091008146 restriction endonucleases Proteins 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 claims description 4
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 claims description 4
- 239000002299 complementary DNA Substances 0.000 claims 1
- 238000010367 cloning Methods 0.000 abstract description 6
- NLTUCYMLOPLUHL-KQYNXXCUSA-N adenosine 5'-[gamma-thio]triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=S)[C@@H](O)[C@H]1O NLTUCYMLOPLUHL-KQYNXXCUSA-N 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000013615 primer Substances 0.000 description 68
- 230000006820 DNA synthesis Effects 0.000 description 63
- 239000000523 sample Substances 0.000 description 29
- 101710176276 SSB protein Proteins 0.000 description 28
- 101710126859 Single-stranded DNA-binding protein Proteins 0.000 description 28
- 238000007792 addition Methods 0.000 description 25
- 238000009739 binding Methods 0.000 description 24
- 230000000694 effects Effects 0.000 description 24
- 230000027455 binding Effects 0.000 description 19
- 238000009396 hybridization Methods 0.000 description 19
- 230000035892 strand transfer Effects 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 239000000758 substrate Substances 0.000 description 11
- 239000011543 agarose gel Substances 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 108091006112 ATPases Proteins 0.000 description 8
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000004544 DNA amplification Effects 0.000 description 7
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- 239000003155 DNA primer Substances 0.000 description 6
- 230000004568 DNA-binding Effects 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 239000000020 Nitrocellulose Substances 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 6
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 6
- 229960005542 ethidium bromide Drugs 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 229920001220 nitrocellulos Polymers 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 238000012287 DNA Binding Assay Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 101150079601 recA gene Proteins 0.000 description 5
- 238000006276 transfer reaction Methods 0.000 description 5
- 108020004638 Circular DNA Proteins 0.000 description 4
- 108020001019 DNA Primers Proteins 0.000 description 4
- 239000003298 DNA probe Substances 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 108010067770 Endopeptidase K Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000006555 catalytic reaction Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 108020003215 DNA Probes Proteins 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010014594 Heterogeneous Nuclear Ribonucleoprotein A1 Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 108091027569 Z-DNA Proteins 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- OSBLTNPMIGYQGY-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;boric acid Chemical compound OB(O)O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O OSBLTNPMIGYQGY-UHFFFAOYSA-N 0.000 description 2
- PGSPUKDWUHBDKJ-UHFFFAOYSA-N 6,7-dihydro-3h-purin-2-amine Chemical group C1NC(N)=NC2=C1NC=N2 PGSPUKDWUHBDKJ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000007474 Multiprotein Complexes Human genes 0.000 description 2
- 108010085220 Multiprotein Complexes Proteins 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 241000282485 Vulpes vulpes Species 0.000 description 2
- 238000003916 acid precipitation Methods 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000011654 magnesium acetate Substances 0.000 description 2
- 229940069446 magnesium acetate Drugs 0.000 description 2
- 235000011285 magnesium acetate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229940070376 protein Drugs 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NLIVDORGVGAOOJ-MAHBNPEESA-M xylene cyanol Chemical compound [Na+].C1=C(C)C(NCC)=CC=C1C(\C=1C(=CC(OS([O-])=O)=CC=1)OS([O-])=O)=C\1C=C(C)\C(=[NH+]/CC)\C=C/1 NLIVDORGVGAOOJ-MAHBNPEESA-M 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- CZVCGJBESNRLEQ-UHFFFAOYSA-N 7h-purine;pyrimidine Chemical compound C1=CN=CN=C1.C1=NC=C2NC=NC2=N1 CZVCGJBESNRLEQ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 206010056740 Genital discharge Diseases 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000589945 Magnetospirillum magnetotacticum Species 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 101100202428 Neopyropia yezoensis atps gene Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000204671 Pyrodictium Species 0.000 description 1
- 241000505673 Scintilla Species 0.000 description 1
- 239000008051 TBE buffer Substances 0.000 description 1
- 241001162933 Therophilus Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000004695 complexes Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940075911 depen Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- -1 nucleotide triphosphates Chemical class 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 108091011138 protein binding proteins Proteins 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
Definitions
- the present invention relates to methods for using RecA protein(s) to catalyze DNA synthesis, repair and amplification reactions.
- RecA+ protein (wild type) is a 38,000 dalton protein found in the bacterium Escherichia coli , which is important for homologous DNA recombination. Most information about its biochemistry and enzymology comes from studies on puri ⁇ fied RecA+ protein. Numerous in vitro studies have shown that RecA+ protein is intimately involved in the pairing reaction between homologous DNA sequences that ultimately leads to homologous recombination events (see Cox et. al. for a recent review of RecA+ protein properties) . It is this pairing reaction that makes RecA+ protein highly use ⁇ ful for DNA diagnostics and therapeutics applications.
- RecA+ protein catalyzes strand exchange between a number of substrates, the most relevant for DNA probe applications being single- and double-stran ⁇ ded DNAs.
- Single-stranded DNA probe
- probe interacts with the homologous portion of the double-stranded ("native") target sequences, initially by forming a recombination intermedi ⁇ ate containing hybridized, partially joined molecules. This is followed by branch migration, and forming of fully hybrid molecules between the original single- and double- stranded DNAs, depending upon the extent of their homology.
- This reaction results in a product that is a hybrid between probe and target.
- Such hybrids can be easily detected using, for example, radio-labeled, enzyme-labeled, chemilu- minescently-labeled, phosphorescently-labeled or fluores- cently-labeled probes.
- RecA-i- protein is particularly well suited for many DNA probe applications because the double- stranded target DNA does not need to be denatured (e.g., by heating) before hybridization.
- RecA+ protein is useful in facilitating the initiation and completion of DNA chain elongation at DNA sequences that are either damaged or difficult to denature.
- the method involves complexing a primer complementary to a 5' end region of the first strand and a primer complementary to a 5' end region of the second strand with RecA protein in the presence of ATP- -S.
- the complexed primers are then reacted in a mix- ture also containing the target sequence, all four dNTPs, RecA protein and DNA polymerase.
- the reaction is conducted below the temperature required for thermal dissociation of the two target strands and continued until a desired degree of amplification of the target sequence is achieved.
- the method of the present invention is particularly useful when the target DNA has inhibitory secondary struc ⁇ ture or otherwise amplification resistant regions.
- One embodiment of the present method includes that the two primers are complementary to the same DNA sequence.
- Another embodiment includes the use of primers containing terminal 5' sequences which are non-complementary to the DNA target sequence. These non-complementary sequences may include sequences coding for restriction endonuclease recognition sites, capture sequences, reporter sequences, RecA protein loading sequences, Z-DNA sequences or double- stranded tails.
- An important advantage of the invention is use of the method for the synthesis/amplification of physically or chemically damaged DNA substrates.
- a preferred embodiment of the invention includes that the RecA protein is the protein product of the recA-803 gene.
- the method of the present invention can also be used to achieve synthesis or amplification of DNA by conducting the DNA synthesis reactions at a constant temperature above about 50°C and below the temperature required for thermal dissociation of the target strands and their respective primers.
- useful forms of the RecA pro ⁇ tein and DNA polymerase can be obtained from Thermus aguaticus .
- the present invention further includes the cloning and identification of the coding sequences for the RecA protein of Thermus aguaticus .
- the RecA coated primers of the present invention also serve as useful probes in hybridization-based diagnostic systems because of their enhanced ability to locate and pair with complementary sequences and sequences in regions of normally inhibitory secondary structure.
- Figure 1 shows the results of the electrophoretic separation of DNA binding reactions comparing the activi ⁇ ties of RecA+ and recA-803 proteins.
- Figure 2A shows the results of ATP hydrolysis reac ⁇ tions comparing the ATPase activity of RecA+ and recA-803 proteins.
- Figure 2B shows the results of strand-transfer reactions comparing the activities of RecA+ and recA-803 proteins.
- Figures 3, 4A and 4B show the results of RecA+ pro ⁇ tein/-double-stranded DNA binding assays.
- Figure 5 illustrates the effects of RecA ⁇ protein and single-strand binding protein on bulk DNA synthesis from single-stranded DNA templates.
- Figure 6 illustrates the effect of recA-803 protein on bulk DNA synthesis from double-stranded linear templates.
- Figure 7 shows the results demonstrating the RecA+ protein enhancement of DNA synthesis from native lambda DNA templates.
- Figure 8 shows the results demonstrating that the enhancement of DNA synthesis by RecA+ protein does not depend on the presence of single-strand binding protein.
- Figure 9 shows the results demonstrating the depen ⁇ dence of RecA+ protein catalyzed DNA synthesis on the presence of specific primers.
- Figures 10 and 11 show results demonstrating RecA+ protein catalyzed single temperature DNA amplification reactions.
- Figure 12 shows results demonstrating that RecA+ enhances product specificity in single temperature amplifi- cation reactions.
- Figure 13 shows the partial sequence of the RecA gene of Aquas pir ilium magnet ot act icum.
- One focus of the present invention is to provide superior RecA+ protein catalysts to facilitate DNA hybrid ⁇ ization and DNA synthesis reactions.
- recA-S03 pro ⁇ tein to be a valuable candidate for such a catalyst.
- the recA-803 mutant gene has been cloned and sequenced, and the protein product over-expressed and purified (Madiraju et. al.) .
- This new recA mutant protein more efficiently forms more stable recombination intermediates between target and probe DNAs than wild-type RecA+ protein as judged by nitro ⁇ cellulose filter binding assays (Madiraju et. al.).
- mutant recA-803 protein catalyzes the pairing reaction with faster kinetics and to a greater final yield than is usu ⁇ ally achieved by the wild-type RecA+ enzyme.
- Large quantities of mutant recA-803 protein have been isolated from E. coli containing a plasmid (Dr. A. John Clark, Dept. Mol. Biology (UC Berkeley) that over-expresses the gene; approximately 40% of the total protein in the bacterial cell is mutant recA-803 protein.
- Example 1 presents gel retardation assay data to examine the relative DNA binding efficiencies of RecA+ and recA-803 proteins.
- RecA+ or recA-803 protein is reacted with the double-stranded linearized DNA of phiX174 under conditions allowing formation of protein/DNA com- plexes.
- the reactions were split into two samples; half of each sample was treated with a detergent, such as SDS, to destroy the protein/DNA complexes.
- the treated and untreated samples were run side-by-side on 0.7% agarose gels (see Materials and Methods) .
- a basis of the gel retardation assay is that DNA/protein complexes migrate much more slowly through the matrix of a gel.
- Example 2 presents data showing that recA-803 protein is also a superior catalyst in comparison to RecA+ protein, in hydrolysis of ATP and in producing significantly greater amounts of DNA strand transfer products.
- the recA-803 pro ⁇ tein exhibits significantly more DNA dependent ATPase acti- vity than the RecA+ protein ( Figure 2A) .
- Example 2B single-stranded phiX-174 virion circular DNA was preincuba- ted with recA-803 or RecA+ protein proteins for 10 minutes at 37°C to form a Radding-type filament (Radding) . The double-stranded target was then added and the strands were transferred with ATPS as a ⁇ ofactor.
- recA-803 catalyzes a significantly greater amount of strand-transfer product in comparison to RecA+ protein.
- the strand-transfer products appear as a discrete band indicated by the arrow in Figure 2B.
- Comparison of lanes 3 and 6 (RecA+ protein) to lane 8 (recA-803 protein) illustrates recA-803 protein's increased efficiency in generating DNA strand transfer products. From this and similar experiments the recA-803 protein appears to produce about 5-7 fold more Form II strand-transfer products than RecA+ protein.
- recA-803 protein a superior catalyst for DNA synthesis, hybridization, diagnostics and therapeu- tics applications. These desirable properties make recA- 803 protein an ideal catalyst to provide rapid and effi ⁇ cient assays for hybridizing DNA probe sequences with native double-stranded DNA targets in solution.
- assays can make use of any separation system (Collins et. al. , Rigas et. al., Leahy et.
- functions of RecA+ protein most likely include facilitating DNA polymerization or recombination through (i) regions of complex or unusual secondary structure, or (ii) chemically or physically damaged DNA sequences.
- RecA Protein's Enhanced Binding to Damaged DNA or DNA having the Z Conformation E. coli RecA+ protein is a major participant in the recognition and subsequent repair of damaged DNA double- helices.
- Certain physical and chemical agents, such as UV light (Lu et. al.) and psoralen (Shi et. al.), which can adduct and/distort pyrimidine bases in double-stranded DNA conformation, are known to increase RecA+ protein binding. RecA+ protein recognition of purine-adducted double-helical DNA has not been examined previously.
- N-acetoxy-N-2- acetylaminofluorene is a potent mutagen and model chemical carcinogen that covalently binds deoxygua- nine residues yielding adducts primarily at the C-8 position (Kriek) .
- This modification causes extensive topological changes and unwinding of the DNA helix by inducing the rotation of the deoxyguanine base from the anti to the syn conformation (Fuchs et. al. , 1976) .
- Energy minimization studies suggest that this rotation may be accompanied by insertion of the heterocyclic adduct into the helix interior causing a bend in the helical axis
- Example 3 describes the results of RecA+ protein/dou- ble-stranded DNA binding assays.
- Blaho et. al. have previ ⁇ ously shown that RecA+ protein preferentially binds to bro- minated or methylated linear synthetic Z-DNA compared with the B-DNA polymers.
- the results of Example 3, presented in Figure 3, illustrate a preferential binding to the bromina- ted substrate, consistent with the results of Blaho et. al.
- the results in Figure 3 show that RecA+ binding to the duplex synthetic DNA at neutral pH with ATP S as a co- factor is enhanced by purine adduction with N-AcO-AAF.
- N-AcO-AAF adducts in the duplex DNA increased RecA+ protein binding to the DNA duplex. Binding was proportional to the degree of N-AcO-AAF adduction in the range of 5-20% N-AcO-AAF adduction.
- Example 4 clearly illustrate RecA+ protein apparent sequence-specificity in preferential binding affinities to the double-stranded oligo-[d(C-A)*d(G-T) ] relative to the duplexes generated from oligo-[d(br 5 C-G) ] or oligo-[d(C-G) ] .
- RecA+ protein shows sequence ( Figures 4A and 4B) and conformation ( Figure 3) specific binding preferences for these DNA duplexes.
- RecA protein accordingly, has valuable diagnostic and therapeutic applications. If the target DNA has been damaged or has unusual secondary structure, traditional methods of DNA hybridization and/or synthesis may be ineffectual.
- the results of the experiments presented in Examples 3 and 4 illustrate the value of using RecA pro ⁇ tein's ability to promote binding to complex DNA and complementary base pairing.
- RecA protein catalyzed DNA amplifi- cation involves incubating DNA target sequences and DNA primers complementary to the target sequence with RecA+ protein or recA-803 protein in the presence of ATP or ATP S at 37°C. These conditions permit RecA-protein-catalyzed Radding-type D-loops or joint molecules between the primers and the tar ⁇ get DNA. These stable RecA-catalyzed joint molecules are elongated with the Klenow fra ment of DNA polymerase I.
- Example 5 describes the enhancing effect of RecA+ pro ⁇ tein on DNA synthesis directed from a single-stranded template.
- the data presented in Figure 5 shows the enhancement of single-stranded DNA synthesis by RecA+ and E. coli single-strand binding (SSB) proteins; the two pro ⁇ teins appear to have a synergistic effect.
- Synthesis on phiX-174 single-stranded circular DNA templates was enhanced by coating the primers with RecA+, thus generating a Radding-type filament.
- Inclusion of E . coli SSB protein in the reaction also enhanced single-stranded DNA directed DNA synthesis as measured by incorporation of [ 3 H]dGTP into high-molecular-weight (cold TCA insoluble) DNA.
- RecA protein The effect of RecA protein on DNA synthesis from a double-stranded DNA (dsDNA) template was also examined (Example 6) .
- the data presented in Figure 6 shows recA-803 protein-enhanced DNA synthesis from a double-stranded template using 18-mer primers.
- the primers were reacted with recA-803 protein (3 ⁇ ) for 5 minutes at 37°C to form filaments before addition of the dsDNA.
- Klenow large fragment of E. coli DNA polymerase I was added.
- RecA-803 protein signifi- cantly enhanced DNA synthesis as judged by increased incor ⁇ poration of [ ⁇ - 35 S]dATP into high-molecular-weight DNA.
- Examples 5 and 6 show that the rates and extent of DNA synthesis can be significantly enhanced by primers coated with RecA+ or recA-803.
- Example 7 demonstrates that RecA protein is able to enhance DNA synthesis from native lambda viral DNA tem ⁇ plates.
- the reactions were assembled at room temperature without the primers.
- RecA+ protein was incubated with the two 25-mer single-stranded primers (PCR01 and PCR02, Table 1).
- ATP-y-S and SSB protein were added to the reaction, followed by the native ⁇ DNA template. Reactions were incubated in a 37°C heat block and equilibrated at 37°C for 3 minutes prior to the addi ⁇ tion of Klenow DNA polymerase.
- Example 7 presents data showing that the ability of RecA protein to enhance DNA synthesis on dsDNA templates is not dependent on the presence of SSB protein.
- the data presented in Figure 8 shows DNA synthesis in the absence of SSB protein (lane 1) and further demonstrates RecA+ pro ⁇ tein's ability to enhance DNA synthesis in short term reac ⁇ tions (8 successive additions of polymerase every 10 mi ⁇ nutes for 80 minutes) .
- the primer dependent nature of the RecA protein cata ⁇ lyzed DNA synthesis is described in Example 8.
- the data presented in Figure 9 shows enhanced native DNA synthesis in polymerase reactions with exonuclease free (US Biochemi- cals) double mutants of the Klenow large fragment of E. coli DNA polymerase I only in the presence of RecA+ protein and primers.
- a 500-bp DNA template was enzymatically synthesized (Amplitaq R kit, Perkin-Elmer-Cetus) using PCROl and PCR02 primer pairs (Table 1) .
- This double-stranded product was used as a simple 500-bp template with 40-mer primers PCROl and PCR02 (Table 1) for DNA synthesis reactions.
- the reac ⁇ tions were incubated for 17.5 hours at 37°C using exonucle- ase-free double mutants of the Klenow large fragment of E . coli DNA polymerase I.
- the data presented in Figure 10 (Example 9) (lane 4) shows a band of newly synthesized DNA products with an electrophoretic mobility and molecular weight matching the 500-bp native ⁇ DNA template.
- the method of the present invention permits the syn ⁇ thesis and amplification of native duplex, i.e. non- denatured, target DNA sequences, in solution, using RecA- catalyzed target hybridization with homologous oligonucleo- tide primer sequences.
- This hybridization reaction posi ⁇ tions the primers for subsequent extension by DNA polymera- ses.
- the reaction is a two-step process and requires opti ⁇ mization of both steps of the reaction: (i) the primer hybridization; and, (ii) the primer extension.
- Target DNA sequences can be obtained by a variety of methods and from many sources, for example: (i) the original target DNA sequence may be synthesized from a single-strand nucleic acid template, such as single-strand DNA or an RNA molecule, by standard procedures (Maniatis et al.); and, (ii) the original target sequence may be ex ⁇ tracted from a cell or tissue source.
- the target DNA se ⁇ quence can also be present in a homogeneous mixture, i.e.. predominantly composed of target sequences, or a heteroge ⁇ neous mixture, i.e., other sequences are present.
- a primer complementary to the target se ⁇ quence is reacted with the target DNA sequence under conditions which allow the RecA protein to catalyze the formation of joint-molecules between the primer and the target DNA.
- This reaction is carried out with native DNA substrates, i.e., the DNA strands are not heat-denatured.
- the multi-stranded structures, whose formation are cata- lyzed by RecA protein, are elongated using the Klenow fragment of DNA polymerase I in the presence of nucleotide triphosphates. RecA protein topologically prepares the hybrid DNA for DNA polymerase elongation.
- free primers complementary to the existing target DNA strands can either bind to an original strand or to the new strand. Once hybridized these complexes are then elongated using DNA polymerase as described above. The process is repeated and the target sequence is synthesized, thus amplified, many times. After a few rounds of amplification, the native target sequence can be detected using a labeled single- stranded DNA probe driven by mass action hybridization and/or by RecA protein/probe complexes in hybridization reactions catalyzed by the RecA protein.
- the reaction can be allowed to proceed for many rounds, providing an amplified product which can be visualized, for example, by electrophoretically resolving the separated reaction components on an agarose gel, followed by staining the separated DNA in the gel with ethidium bromide.
- RecA+ and recA-803 proteins in DNA amplification and DNA synthetic reactions is that these proteins strongly facilitate efficient hybridization of the single-stranded DNA primer to target DNA sequences. Fur ⁇ ther, these proteins prepare the DNA primer-native-target complex topologically for extension. Because of the topo- logical effects of RecA protein, cellular DNA polymerases, such as Klenow fragment of E. coli DNA polymerase I, can elongate the primer as the template strand is unwound. This reaction is simpler than amplification reactions which require heating to provide single strand templates and cooling to allow hybridization of the primers.
- RecA enhanced DNA syntheses are to amplify normal, light-damaged, or chemical ⁇ ly-damaged DNA sequences using RecA-catalysis to properly position primers on their homologous targets for subsequent extension by DNA polymerases.
- Another advantage of the use of RecA protein-catalyzed DNA synthesis is the elimination of the requirement for multiple cycles of high-temperature thermal denaturation and renaturation (Saiki et al.).
- a second important application, as discussed above, is the ability of RecA protein to topologically prepare DNA for DNA synthesis; in particular, DNA having conformations or secondary structures which are difficult to synthesize or amplify by traditional methods, such as heat denatur- ation.
- RecA protein-catalyzed reactions takes advantage of the ability of the RecA pro ⁇ tein/DNA primer complexes to efficiently find complementary sequences.
- the protein/primer complexes can, for example, be used as probes in diagnostic assays which depend on the identification of sequences in a sample based on their complementarity to the primer.
- the bound complex can then be stabilized and identified by a variety of methods, such as by antibodies directed against the recA-803 protein.
- RecA protein refers to a family of RecA-like proteins all having essentially the same functions, particularly: (i) the protein's ability to properly position primers on their homologous targets for subsequent extension by DNA polymerases; (ii) the ability of RecA protein to topologically prepare DNA for DNA synthesis; and, (iii) the ability of RecA protein/DNA primer complexes to efficiently find and bind to complemen ⁇ tary sequences.
- the best characterized RecA protein is from E. coli ; in addition to the wild-type protein a number of mutant recA proteins have been identified (eg. recA-803) . Further, many organisms have such RecA-like proteins (see below) .
- RecA protein catalyzed DNA synthesis is use in enhancing DNA polymerase amplification reactions at a constant elevated temperature using a heat- stable DNA polymerase.
- Heat-stable DNA polymerases have been isolated from a variety of sources, including: Thermus aguaticus (U.S. Biochemicals) , Bacillus ⁇ tearo- ther ophilus, Sulpholuhus , or Pyrodictium . Generally the activities of these enzymes are heat-stable up to about 95°C. A system such as this may allow amplification of DNA sequences having strong inhibitory structures or DNA se ⁇ quences known to produce artifacts (McConlogue et al; Shuldiner et al.). E.
- coli RecA protein has a half-life of minutes at 52°C and, accordingly, is too heat-sensitive for use at elevated temperatures; accordingly, a heat-stable RecA protein is required.
- a heat-stable RecA protein needs to retain its activity over essentially the same tempera ⁇ ture range as the DNA polymerase with which it is being used (eg. up to about 95°C) .
- the RecA protein from Thermus aguaticus has been identified and the gene encoding it cloned.
- Southern blot analysis of Thermus aguaticus genomic DNA was performed using the Aguaspir lium magnetotacticum RecA gene as a probe (Example 10) .
- the Aquaspirillum magnetotacticum gene is unusually G-C rich and is likely a better match for the T . aguaticus RecA gene than the E. coli RecA gene.
- Single DNA bands were identified, by hybridization with the probe, in each of the following digests: 12-15 kb, BamHI; 5 kb, Hindlll; and 1.5 kb, Sstl.
- T. aguaticus RecA genomic DNA was purified from T. aguaticus, cut with the restriction endonuclease BamHI (Maniatis et al.), and then cloned into the EMBL Lambda cloning system (Promega) .
- the large -Ba ⁇ I fragment (15kb) containing the T. aguaticus RecA gene from T. aguaticus was isolated from a phage DNA-containing clone which strongly hybridized to the probe under stringent conditions of hybridization washing.
- the gene is being subcloned into M13 vectors for complete sequencing.
- the gene is also being subcloned into ProtocloneTM lambda gtll vectors (Promega) for expression and identification of the RecA protein.
- T. aguaticus RecA protein The ability of the T. aguaticus RecA protein to improve the length of the target and the final yield of the products in DNA amplification reactions is tested as described above for RecA proteins.
- tem ⁇ plates having significant secondary structures are used as targets, such as human tRNA genes and the cluster of 21 tRNA genes found in a 2.5-kbp fragment of DNA from Bacillus subtili ⁇ (Green et al.).
- Synthetic polymers including poly-[d(C-G) ] and poly- [d(br 5 C-G)], were synthesized enzymatically with DNA poly ⁇ merase from poly-[d(I-C) ] templates (Pharmacia) and charac- terized as described previously (Zarling et. al., 1984a; 1984b; Zarling et al. 1990).
- Poly-[d(C-A)»d(G-T) ] was pur ⁇ chased from Pharmacia-P.L.
- Polynucleotides were sonicated to an average size of 550 base pairs (bp) as determined by agarose gel electrophoresis to generate oligonucleotides.
- Primers were either purchased (eg. , the primers in Table 1 are obtained from Cetus Perkin-El er) or prepared using commercially available automated oligonucleotide synthesizers. Alternatvely, custom designed synthetic primers may be purchased, for example, from Synthetic Genetics (San Diego, CA) .
- This example describes the results of ATPase and strand-transfer reactions comparing the activities of RecA+ and recA-803 proteins.
- BSA bovine serum albumin
- the reactions were incubated at 37°C for 30 minutes in 0.6 ml microcentrifuge tubes. The reactions were terminat ⁇ ed by chilling to 0°C followed by the addition of 12 ⁇ l of 25 mM EDTA containing 3 mM each of unlabelled ATP, ADP and AMP as carrier. A 10 ⁇ l aliquot of each reaction was then spotted onto plastic-backed TLC sheets of PEI-cellulose F (Pharmacia) and the TLC sheets developed in a solvent containing 0.5 M LiCl and 0.25 M formic acid. Radioactive products were visualized by autoradiography. The areas corresponding to the liberated inorganic phosphate were scraped off of the TLC sheets and counted in a scintilla ⁇ tion counter.
- Example 3 Increased Binding of RecA+ Protein to oligo-rdfbr 5 C-G) 1 and to N-acetoxy-N-2-acetylaminofluorene Modified DNA
- This example describes the results of RecA+ protein/- double-stranded DNA binding assays which indicate the increased ability of the RecA+ protein to bind to light- damaged DNA, chemically-damaged DNA or DNA having the Z-conformation.
- the DNA substrates used in the binding assays were end-labelled using adenosine [y-P 32 ] triphosphate (New England Nuclear) by the method of Silberklang et. al.
- the reactions were initiated by the addition of the RecA+ protein at 37°C and incubated for the time periods specified in Figure 3.
- Figure 3 illustrates the results of the DNA binding assay ' s.
- the symbols in Figure 3 represent the following DNA substrates: open squares, oligo-[d(br 5 C-G) ] ; closed squares, N-AcO-AAF adducted oligo-[d(br 5 C-G) ] ; open triangles, oligo[d(C-G) ] ; closed triangles, N-AcO-AAF adducted oligo[d(C-G) ] .
- Figure 3 shows the increased binding of RecA+ protein to chemically modified (N-AcO-AAF adducted) DNA relative to unmodified DNA; further, the figure illustrates the in ⁇ creased binding of RecA+ protein to oligo-[d(br 5 C-G) ] , having a Z-DNA conformation, relative to oligo[d(C-G) ] , having a B-DNA conformation.
- This example describes the results of DNA binding assays which demonstrate the preferential binding of RecA+ prptein to certain double-stranded DNAs containing alterna ⁇ ting sequences of purines and pyrimidines [e.g., (PuPyPuPyPuPyPuPy) .
- the DNA binding reactions had a total volume of 50 ⁇ l and contained the following components: 0.35 ⁇ M RecA+ pro- tein; 0.7 ⁇ M DNA (molecules) substrate; TEA buffer (see above) ; and 20 ⁇ M ATP-p-S.
- the reactions were carried at 20°C and terminated by filtration of the protein/DNA com ⁇ plexes on nitrocellulose filters (described in Example 3) at the time points illustrated in Figure 4A.
- the DNA binding reactions had a total volume of 50 ⁇ l and contained the following components: 0 to 5.0 ⁇ M RecA+ protein; 1.0 ⁇ M DNA substrate (molecules); TEA buffer (see above) ; and 20 ⁇ M ATP-p-S.
- the reactions were carried at 20°C for 20 minutes and terminated by filtration of the pro ⁇ tein/DNA complexes on nitrocellulose filters (described in Example 3) .
- Figures 4A and 4B clearly illustrate the binding pre ⁇ ference of RecA+ protein to the following sequences of alternating purines and pyrimidines, in decreasing order of preference: double stranded oligo-[d(C-A)»[d(G-T) ] , having the right-handed B-conformation; oligo-[d(br 5 C-G) ] , having the left-handed Z-conformation; and, oligo-[d(C-G) ] having the right-handed B-conformation.
- This example describes the results demonstrating an enhancing effect of RecA+ protein on bulk DNA synthesis from a single-stranded template.
- the 24-mer primer [d(AGCGGATAACAATTTCACACAGGA) ] was coated with RecA+ and protein using ATP-y-S .
- the coated primer was added to M13mpl8 single-stranded DNA in a reaction mixture containing rATP; the RATP regenerating system PEP/PK (Boehringer Mannheim) ; dNTPs and [ 3 H]dGTP (New England Nuclear) ; E . coli single-strand binding (SSB) pro- tein (U.S. Biochemical Corporation).
- the total reaction volume was 26.25 ⁇ l. These conditions were varied by the presence or absence of RecA+ protein and SSB protein (see Figure 5) . After 4 minutes at 37°C, 0.5 units of the Klenow large fragment of DNA polymerase I (New England Biolabs) was added.
- Reactions were incubated at 37°C and sampled at 5 minute intervals for 15 minutes. Reaction samples were collected by cold 5% Trichloroacetic acid precipitation of the 3 H-labeled DNA and filtration on glass filters (Schleicher and Schuell, Inc.). The amount of [ 3 H]dGTP incorporated into newly synthesized high-molecular-weight DNA was determined by counting the glass filters in a toluene-based scintillation mix using a Packard P2000 liquid scintillation counter. The results of the reactions are presented in Figure 5.
- the components of the reactions were as follows: open circles, DNA polymerase I; closed circles, DNA polymerase I and SSB protein; open squares, DNA polymerase I and RecA+ protein; and, the closed squares, DNA polymerase I, RecA+ protein, and SSB protein.
- This example describes the results demonstrating the enhancement of bulk DNA synthesis by RecA+-803 protein.
- the double-stranded linear template for these reac ⁇ tions was plasmid pJC801-886, containing the coding se- quences for the E. coli RecA gene, cut with restriction endonuclease Sail resulting in an 8 kilobase (kb) linear fragment.
- primer A [d(ATGCGACCCTTGTGTATC) ] ; and, primer B [d(GTGGTGGGTAGCAAACC) ] .
- the primers were coated with RecA+ protein (3.0 ⁇ M) , in 30 mM Tris-acetate, 60 mM sodium acetate, 10 mM Mg acetate, further containing the PEP/PK (Boehringher Mannheim) rATP regenerating system, for 5 minutes at 37°C.
- the DNA synthesis reactions were performed in a total reaction volume of 32 ⁇ l.
- Five units of Klenow DNA polymerase I were added. Reactions were incubated at 37°C for 30 minutes and sampled at the time points indicated in Figure 6. Reaction samples were collected by cold 5% Trichloroacetic acid precipita- tion of the 35 S-labeled DNA and filtration on glass filters (Schleicher and Schuell, Inc.). The amount of [ 35 S]dATP incorporated into newly synthesized high-molecular-weight DNA was determined by counting the glass filters in a toluene-based scintillation mix using a Packard P2000 liquid scintillation counter.
- Lambda DNA Templates This example describes the results demonstrating the RecA+ protein enhancement of DNA synthesis from native lambda DNA templates using 25-mer primers.
- the primer sequences (Cetus-Perkin Elmer, Norwalk, CT) were derived from the lambda viral DNA sequence.
- the lamb ⁇ da viral genome is approximately 48.5 kb.
- the DNA segment targeted by the primers is 500 base pair (bp) , including the primer sequences, which is about 1% of the total lambda genome.
- RecA+ protein was bound to the single-stranded DNA primers under the following conditions: 0.66 ⁇ M RecA+ pro ⁇ tein was incubated with 1 ⁇ M final concentration of each primer (2 ⁇ M total) . The reaction mixture was incubated for 10 minutes at 22°C. RecA+ protein was effectively bound to the single-stranded primers under these conditions as evidenced by gel retardation of the primer/RecA+ protein complexes.
- 1 ⁇ M final concentration ATP-y-S and 0.094 mM final concentration of SSB protein was added to the reaction, followed by the addition of 0.5 ⁇ g lambda viral genomic DNA (New England Biolabs) .
- Figure 7 shows that lambda DNA synthesis was enhanced by the inclusion of RecA+ protein.
- the enhancement is in ⁇ dicated by an increased concentration of DNA products in the lanes containing RecA+ protein; as evidenced by en- hanced ethidium bromide staining.
- reaction conditions were as described in section A above.
- the reaction mixtures were equilibrated at 37°C for 3 minutes.
- DNA synthesis reactions were initiated by the addition of 1 unit Klenow DNA polymerase I (Klenow) .
- the reactions were maintained at 37°C.
- Klenow Klenow DNA polymerase I
- the reactions were supplemented with 1 unit of Klenow at 10 minute intervals over the 80 minute course of the reaction.
- Each reaction received 8 units of Klenow including the initial addition of 1 unit.
- the following specific reaction conditions were used to test the effect of E . coli single-strand binding (SSB) protein on DNA synthesis in the presence of RecA+ protein.
- the first reaction (lane 1, Figure 8) contained no SSB pro ⁇ tein.
- the second reaction (lane 2, Figure 8) contained 0.094 ⁇ M SSB protein added to the reaction after the addi ⁇ tion of the RecA+ protein primer.
- the third reaction was a control reaction which contained neither RecA+ protein nor SSB protein (lane 3, Figure 8). All the reactions contained 1 mM ATP-/-S and were incubated at 37 °C for 80 minutes.
- Lane 8 The results of the above reactions are shown in Figure 8.
- the samples loaded in each lane were described above.
- Lane 4 contained a standard 1 kb molecular weight ladder (BRL) .
- BTL 1 kb molecular weight ladder
- the appearance of large molecular weight products in lanes 1 and 2 clearly demonstrates that the DNA synthe ⁇ sis reaction is not dependent on the presence of SSB pro ⁇ tein.
- Lane 3 does, however, indicate the reliance of the reaction on the presence of RecA+ protein.
- Example 8 RecA+ protein Enhances Primer Dependent DNA Synthesis at 37°C This example describes the results illustrating the dependence of the DNA synthesis reactions on the presence of both RecA+ protein and the lambda-specific primers.
- the reaction conditions were essentially as described in Example 7A with the following exceptions.
- the first reaction contained RecA+ protein, but the primers were omitted (lane 1, Figure 9) .
- the second reaction contained primers but no RecA+ protein (lane 2, Figure 9) .
- the third reaction contained both RecA-i- protein and the primers (lane 3, Figure 9) .
- the reaction mixtures were equilibrated at 37°C for 3 minutes. DNA synthesis reactions were initiated by the addition of 1 unit of exonuclease-free E. coli DNA polymer ⁇ ase I (a double mutant of the large Klenow fragment, the enzyme is available from U.S. Biochemicals) . The reactions were maintained at 37°C.
- reaction Following the initial addition of polymerase, the reactions were each supplemented with additional units of Klenow at ten minute intervals. Reactions were incubated at 37°C for a total of 72 hours. The 28 ⁇ l samples were treated with proteinase K, as above, before being loaded for electrophoretic separation.
- Example 9 RecA+ Facilitated DNA Amplification at 37°C
- the results in this example illustrate the enhancement of DNA synthesis from a 500 bp lambda target sequence by RecA+ protein.
- the reaction conditions were essentially as described in Example 7A with the following exceptions. All the reac- tions contained 0.5 ⁇ g of a 500 bp template, corresponding to nucleotides 7131-7630 of the lambda genome which had been purified from the product of a J. aguaticus DNA poly ⁇ merase I-catalyzed thermal amplification using lambda DNA template (Mullis) , replacing the native lambda genomic DNA.
- the first two reactions contained no RecA+ protein (lanes 2 and 3, Figure 10).
- the third reaction contained 0.66 ⁇ M final concentration RecA+ protein and no SSB protein (lane 4, Figure 10) .
- the fourth reaction contained 0.66 ⁇ M final concentration RecA+ protein and 0.094 ⁇ M final concentration SSB protein (lane 5, Figure 10).
- reaction mixtures were equilibrated at 37°C for 3 minutes.
- DNA synthesis reactions were initiated by the addition of 1 unit of exonuclease-free E. coli DNA poly ⁇ merase I (U.S. Biochemicals) .
- the reactions were main ⁇ tained at 37°C.
- the reactions were supplemented with 1 unit of Klenow each 10 minutes for an additional 70 minutes.
- the time course of the reaction was 17.5 hours.
- Samples were trea ⁇ ted with proteinase K, as above, before being loaded for electrophoretic separation.
- the concentrations of these components in the reaction mix were as follows: 0.66 ⁇ M RecA+ protein; 0.094 ⁇ M SSB protein; 1 ⁇ M ATP--S; 2 ⁇ M 40-mer primers; 2 ⁇ M 25-mer primers; 0.5 ⁇ g 500 bp template; 1 unit/additions of 8 units total exonuclease-free DNA polymerase I.
- the reaction numbers correspond to the lane numbers shown in Figure 11.
- All the reactions contained 0.5 ⁇ g of a 500 bp template, corresponding to nucleotides 7131-7630 of the lambda genome which had been purified from the product of a T. aguaticus DNA polymerase I-catalyzed thermal amplification using lambda DNA template (Mullis) , replacing the native lambda genomic DNA.
- aguaticus DNA polymerase I-catalyzed thermal amplification using lambda DNA template (Mullis) replacing the native lambda genomic DNA.
- reaction 1 contained ATP-p-S and lacked RecA+ and SSB pro ⁇ tein (lanes 1, Figure 12) ;
- reaction 2 contained ATP- -S and SSB protein and lacked RecA+ protein (lane 2 , Figure 12);
- reaction 3 contained ATP-y-S and RecA+ and lacked SSB pro ⁇ tein (lane 3, Figure 12); and, reaction 4 contained all of the reaction components (lane 4, Figure 12).
- PCR03A nucleotides 7351 through 7390 of the native lambda genome
- PCR03A is a 40-mer corresponding to an internal DNA sequence of the 500 base pair lambda template used in the above amplification reaction. The membrane was then autoradiographed.
- This example describes the identification of the T. aguaticus RecA gene by Southern hybridization analysis and the subsequent cloning of the gene.
- Genomic DNA was purified from T. aguaticus and was digested with the following restriction enzymes: BamHI, Hindlll, and Sstl. The digested DNA was loaded onto a 0.8% agarose gel, electrophoresed, and the DNA fragments transferred to a nitrocellulose membrane (Maniatis et al.) .
- the RecA gene from Aguaspirillum magneto ⁇ tacticum which has a 61.6% homology to the RecA gene of E. coli (A. Berson, M. Peters, and N. Waleh, all of SRI International, personal communication) was used; A. magne ⁇ totacticum has codon usage similar to T. aguaticus .
- the probe consisted of the sequence shown in Figure 13 plus an additional 800 bases of uncharacterized genomic A. magneto ⁇ tacticum DNA. The probe was radioactively labeled using nick-translation (Bethesda Research Laboratories) .
- Southern hybridization was performed using standard tech ⁇ niques (Maniatis et al. , 1987) at 42°C in 20% f ⁇ rmamide. The hybrids were washed under stringent conditions at 55°C in 0.1 x SSC and 0.1% SDS. The autoradiogram showed only a single band for each restriction digest. The DNA bands that hybridized to the probe were 12-15 kb, 5 kb and 1.5 kb for the Bam HI, Hind III, and Sst I digests, respectively. To clone this RecA gene, the above-described -BamHI T. aguaticus genomic DNA was cloned into the EMBL Lambda cloning system (Promega) .
- the resulting phage vectors were plated and plaques generated.
- the phage DNA was trans ⁇ ferred to nitrocellulose filters (plaque lifting, Maniatis et al.).
- the Aguaspirillum magnetotac ⁇ ticum recA gene ( Figure 13) was used as a probe for the Thermus aguaticus recA gene.
- the nitrocellose filters were hybridized with the labeled probe. From a phage DNA- containing clone which strongly hybridized to the probe under stringent conditions of hybridization washing, a large -BamHI fragment (15kb) containing the T. aguaticus RecA gene was isolated.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
- Yarns And Mechanical Finishing Of Yarns Or Ropes (AREA)
- Inorganic Fibers (AREA)
- Woven Fabrics (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La présente invention se rapporte à un procédé pour effectuer l'amplification, facilitée par une protéine RecA, d'une séquence cible d'ADN bicaténaire possédant des premier et second brins complémentaires, chaque brin comportant des extrémités 5' et 3'. Ce procédé consiste à complexer une amorce complémentaire d'une région terminale 5' du premier brin, et une amorce complémentaire d'une région terminale 5' du second brin avec la protéine RecA et en présence d'ATP-gamma-S. Les amorces complexées sont amenées à réagir dans un mélange contenant aussi la séquence cible, les quatre dNTP, la protéine RecA et la polymérase d'ADN. La réaction se fait à une température inférieure à celle requise pour la dissociation thermique des deux brins cibles, et se poursuit jusqu'à ce qu'un degré d'amplification souhaité de la séquence cible soit atteint. La présente invention comprend en outre le clonage et l'identification des séquences codant pour la protéine RecA de Thermus aquaticus.The present invention relates to a method for performing RecA protein-mediated amplification of a double-stranded DNA target sequence having complementary first and second strands, each strand having 5' and 3' ends. This method consists in complexing a primer complementary to a 5' terminal region of the first strand, and a primer complementary to a 5' terminal region of the second strand with the RecA protein and in the presence of ATP-gamma-S. The complexed primers are reacted in a mixture also containing the target sequence, the four dNTPs, the RecA protein and the DNA polymerase. The reaction proceeds at a temperature below that required for thermal dissociation of the two target strands, and continues until a desired degree of amplification of the target sequence is achieved. The present invention further includes the cloning and identification of RecA protein coding sequences from Thermus aquaticus.
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US520321 | 1990-05-07 | ||
US07/520,321 US5223414A (en) | 1990-05-07 | 1990-05-07 | Process for nucleic acid hybridization and amplification |
PCT/US1991/002626 WO1991017267A1 (en) | 1990-05-07 | 1991-04-17 | Process for nucleic acid hybridization and amplification |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0481065A1 true EP0481065A1 (en) | 1992-04-22 |
EP0481065B1 EP0481065B1 (en) | 1996-10-16 |
Family
ID=24072098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP91910088A Expired - Lifetime EP0481065B1 (en) | 1990-05-07 | 1991-04-17 | Process for nucleic acid hybridization and amplification |
Country Status (6)
Country | Link |
---|---|
US (1) | US5223414A (en) |
EP (1) | EP0481065B1 (en) |
JP (1) | JP3010738B2 (en) |
CA (1) | CA2056983C (en) |
DE (1) | DE69122712T2 (en) |
WO (1) | WO1991017267A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5994076A (en) * | 1997-05-21 | 1999-11-30 | Clontech Laboratories, Inc. | Methods of assaying differential expression |
US6489455B2 (en) | 1997-05-21 | 2002-12-03 | Clontech Laboratories, Inc. | Methods of assaying differential expression |
WO2006081583A2 (en) * | 2005-01-28 | 2006-08-03 | Helicos Biosciences Corporation | Methods and compositions for improving fidelity in a nucleic acid synthesis reaction |
Families Citing this family (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0612352T3 (en) * | 1990-05-07 | 1997-06-30 | Daikin Ind Ltd | Diagnostic applications of double-D loop formation |
US5510473A (en) * | 1990-11-09 | 1996-04-23 | The United States Of American As Represented By The Secretary Of Health And Human Services | Cloning of the recA gene from thermus aquaticus YT-1 |
US5506098A (en) * | 1991-09-04 | 1996-04-09 | Daikin Industries, Ltd. | In situ hybridization method |
CA2131630A1 (en) * | 1992-03-10 | 1993-09-30 | Yury E. Khudyakov | Exchangeable template reaction |
CA2118513A1 (en) * | 1992-04-24 | 1993-11-11 | David A. Zarling | In vivo homologous sequence targeting in eukaryotic cells |
US20020108136A1 (en) * | 1997-03-21 | 2002-08-08 | Sri | Transgenic animals produced by homologous sequence targeting |
DE4216949C2 (en) * | 1992-05-22 | 1997-07-24 | Christoph Prof Dr Dr Cremer | Non-enzymatic method for in situ hybridization on specific samples |
US5674992A (en) * | 1992-08-28 | 1997-10-07 | Cornell Research Foundation, Inc. | CDNA encoding a recA homolog in eukaryotes |
US5491086A (en) * | 1993-05-14 | 1996-02-13 | Hoffmann-La Roche Inc. | Purified thermostable nucleic acid polymerase and DNA coding sequences from pyrodictium species |
US5965361A (en) * | 1993-12-28 | 1999-10-12 | Daikin Industries, Ltd. | In-situ hybridization method using RecA protein and RecA protein having marker or ligand for use in said method |
KR100230718B1 (en) * | 1994-03-16 | 1999-11-15 | 다니엘 엘. 캐시앙, 헨리 엘. 노르호프 | Isothermal strand displacement nucleic acid amplification |
ATE272720T1 (en) | 1996-08-29 | 2004-08-15 | Napro Biotherapeutics Inc | METHOD FOR FINDING, DETECTING, ENRICHMENT AND/OR ISOLATING TARGET NUCLEIC ACID SEQUENCES USING RECOMBINASE SIMILAR TO RECA |
US5948653A (en) * | 1997-03-21 | 1999-09-07 | Pati; Sushma | Sequence alterations using homologous recombination |
EP1165760A2 (en) * | 1999-03-12 | 2002-01-02 | McGill University | A method for increasing the processivity of a dna- or rna-dependent polymerase and compositions therefor |
AU2001227679A1 (en) * | 2000-02-25 | 2001-09-03 | General Atomics | Mutant nucleic binding enzymes and use thereof in diagnostic, detection and purification methods |
US20020132350A1 (en) * | 2000-09-14 | 2002-09-19 | Pioneer Hi-Bred International, Inc. | Targeted genetic manipulation using Mu bacteriophage cleaved donor complex |
US20020132259A1 (en) * | 2001-02-21 | 2002-09-19 | Wagner Robert E. | Mutation detection using MutS and RecA |
EP1414840A4 (en) * | 2001-03-27 | 2005-04-13 | Univ Delaware | Genomics applications for modified oligonucleotides |
WO2002086167A1 (en) * | 2001-04-20 | 2002-10-31 | The Penn State Research Foundation | Methods for nucleic acid manipulation |
US7468244B2 (en) * | 2001-09-27 | 2008-12-23 | University Of Delaware | Polymorphism detection and separation |
US7297485B2 (en) * | 2001-10-15 | 2007-11-20 | Qiagen Gmbh | Method for nucleic acid amplification that results in low amplification bias |
US7244562B2 (en) * | 2001-11-01 | 2007-07-17 | Gene Check, Inc. | RecA assisted detection of mutations, single nucleotide polymorphisms and specific sequences |
EP1992706B1 (en) * | 2002-02-21 | 2014-11-19 | Alere San Diego, Inc. | Recombinase polymerase amplification |
US8030000B2 (en) | 2002-02-21 | 2011-10-04 | Alere San Diego, Inc. | Recombinase polymerase amplification |
US7399590B2 (en) | 2002-02-21 | 2008-07-15 | Asm Scientific, Inc. | Recombinase polymerase amplification |
JP4455335B2 (en) * | 2002-09-17 | 2010-04-21 | 株式会社アイシン・コスモス研究所 | Nucleic acid amplification method and single nucleotide polymorphism detection method |
JP2004113108A (en) * | 2002-09-26 | 2004-04-15 | Aisin Seiki Co Ltd | Method for collecting dna |
AU2005218507A1 (en) * | 2004-02-28 | 2005-09-15 | Chang-Ning J. Wang | Nucleic acid complexes |
ES2718482T3 (en) | 2004-06-01 | 2019-07-02 | Alere San Diego Inc | Recombinase polymerase amplification kit |
JP2008501679A (en) | 2004-06-02 | 2008-01-24 | エーエスエム サイエンティフィック, インコーポレイテッド | 2'-nitrobenzyl modified ribonucleotide |
US7700281B2 (en) * | 2004-06-30 | 2010-04-20 | Usb Corporation | Hot start nucleic acid amplification |
JP4534138B2 (en) * | 2004-12-21 | 2010-09-01 | アイシン精機株式会社 | Method for activating protein derived from extreme thermophile and its use in nucleic acid amplification reaction |
ES2420831T3 (en) | 2005-07-25 | 2013-08-27 | Alere San Diego, Inc. | Procedures for multiplexing the extension of recombinase polymerase |
US20080220421A1 (en) * | 2006-02-27 | 2008-09-11 | Salinas Frank G | Isothermal screening for nucleic acids associated with diseases and conditions of the gi tract |
US20070202522A1 (en) * | 2006-02-27 | 2007-08-30 | Salinas Frank G | Isothermal screening of tumor cell related nucleic acids |
US20080003600A1 (en) * | 2006-02-27 | 2008-01-03 | Salinas Frank G | Isothermal screening of breast cancer related nucleic acid |
US20090061413A1 (en) * | 2006-02-27 | 2009-03-05 | Salinas Frank G | Isothermal screening of hiv-1 related nucleic acids |
CA2650993C (en) | 2006-05-04 | 2015-06-16 | Asm Scientific, Inc. | Recombinase polymerase amplification |
WO2009052214A2 (en) * | 2007-10-15 | 2009-04-23 | Complete Genomics, Inc. | Sequence analysis using decorated nucleic acids |
US8383345B2 (en) | 2008-09-12 | 2013-02-26 | University Of Washington | Sequence tag directed subassembly of short sequencing reads into long sequencing reads |
US9309566B2 (en) | 2010-12-17 | 2016-04-12 | Life Technologies Corporation | Methods, compositions, systems, apparatuses and kits for nucleic acid amplification |
US9334531B2 (en) | 2010-12-17 | 2016-05-10 | Life Technologies Corporation | Nucleic acid amplification |
US9309557B2 (en) | 2010-12-17 | 2016-04-12 | Life Technologies Corporation | Nucleic acid amplification |
WO2010135310A1 (en) | 2009-05-20 | 2010-11-25 | Biosite Incorporated | Dna glycosylase/lyase and ap endonuclease substrates |
EP2438196B1 (en) | 2009-06-05 | 2016-12-21 | Alere San Diego, Inc. | Recombinase polymerase amplification reagents and kits |
US9074251B2 (en) | 2011-02-10 | 2015-07-07 | Illumina, Inc. | Linking sequence reads using paired code tags |
EP3147374B1 (en) | 2010-12-17 | 2019-01-30 | Life Technologies Corporation | Methods for nucleic acid amplification |
WO2012106546A2 (en) | 2011-02-02 | 2012-08-09 | University Of Washington Through Its Center For Commercialization | Massively parallel continguity mapping |
EP3978620A1 (en) | 2011-04-07 | 2022-04-06 | Abbott Diagnostics Scarborough, Inc. | Monitoring recombinase polymerase amplification mixtures |
EP3461910B1 (en) | 2012-04-19 | 2020-08-26 | Life Technologies Corporation | Nucleic acid amplification |
CN109486902B (en) | 2012-04-19 | 2023-02-28 | 生命技术公司 | Nucleic acid amplification |
US9012022B2 (en) | 2012-06-08 | 2015-04-21 | Illumina, Inc. | Polymer coatings |
US8895249B2 (en) | 2012-06-15 | 2014-11-25 | Illumina, Inc. | Kinetic exclusion amplification of nucleic acid libraries |
EP3257952B1 (en) | 2012-09-11 | 2020-02-12 | Life Technologies Corporation | Nucleic acid amplification |
WO2014043143A1 (en) | 2012-09-11 | 2014-03-20 | Life Technologies Corporation | Nucleic acid amplification |
US9683230B2 (en) | 2013-01-09 | 2017-06-20 | Illumina Cambridge Limited | Sample preparation on a solid support |
US9512422B2 (en) | 2013-02-26 | 2016-12-06 | Illumina, Inc. | Gel patterned surfaces |
CA3160098A1 (en) | 2013-03-11 | 2014-10-09 | Cue Health Inc. | Systems and methods for detection and quantification of analytes |
US10545161B2 (en) | 2013-03-11 | 2020-01-28 | Cue Health Inc. | Systems and methods for detection and quantification of analytes |
US9623409B2 (en) | 2013-03-11 | 2017-04-18 | Cue Inc. | Cartridges, kits, and methods for enhanced mixing for detection and quantification of analytes |
WO2014142850A1 (en) | 2013-03-13 | 2014-09-18 | Illumina, Inc. | Methods and compositions for nucleic acid sequencing |
CA2931533C (en) * | 2013-12-09 | 2023-08-08 | Illumina, Inc. | Methods and compositions for targeted nucleic acid sequencing |
CA2932283A1 (en) | 2013-12-20 | 2015-06-25 | Illumina, Inc. | Preserving genomic connectivity information in fragmented genomic dna samples |
CN106103713B (en) | 2014-02-03 | 2021-05-28 | 赛默飞世尔科技波罗的海封闭股份公司 | Method for controlled DNA fragmentation |
USD745423S1 (en) | 2014-05-12 | 2015-12-15 | Cue Inc. | Automated analyzer test cartridge and sample collection device for analyte detection |
CN106574305B (en) | 2014-06-13 | 2021-03-02 | 生命技术公司 | Multiplex nucleic acid amplification |
EP3715468A1 (en) | 2014-06-13 | 2020-09-30 | Illumina Cambridge Limited | Methods and compositions for preparing sequencing libraries |
US10577603B2 (en) | 2014-06-30 | 2020-03-03 | Illumina, Inc. | Methods and compositions using one-sided transposition |
WO2016040602A1 (en) | 2014-09-11 | 2016-03-17 | Epicentre Technologies Corporation | Reduced representation bisulfite sequencing using uracil n-glycosylase (ung) and endonuclease iv |
CA2962941C (en) | 2014-09-29 | 2022-06-14 | Illumina Cambridge Limited | Recombinase mutants |
RU2736728C2 (en) | 2014-10-17 | 2020-11-19 | Иллумина Кембридж Лимитед | Transposition with preservation of gene adhesion |
CA2967525A1 (en) | 2014-11-11 | 2016-05-19 | Illumina Cambridge Ltd. | Methods and arrays for producing and sequencing monoclonal clusters of nucleic acid |
EP3234187B1 (en) | 2014-12-15 | 2021-02-17 | Illumina, Inc. | Method for single molecular placement on a substrate |
CN107849598B (en) | 2015-05-29 | 2021-12-14 | 伊卢米纳剑桥有限公司 | Enhanced utilization of surface primers in clusters |
US10344336B2 (en) | 2015-06-09 | 2019-07-09 | Life Technologies Corporation | Methods, systems, compositions, kits, apparatus and computer-readable media for molecular tagging |
BR122020004273B1 (en) | 2015-07-17 | 2022-11-29 | Cue Health Inc | SAMPLE ANALYSIS CARTRIDGE |
EP3387147A1 (en) | 2015-12-09 | 2018-10-17 | Life Technologies Corporation | Detection and quantification of nucleic acid molecules associated with a surface |
WO2017121836A1 (en) | 2016-01-15 | 2017-07-20 | Thermo Fisher Scientific Baltics Uab | Thermophilic dna polymerase mutants |
ES2903045T3 (en) | 2016-03-28 | 2022-03-30 | Illumina Inc | recombinase mutants |
ES2861350T3 (en) | 2016-03-28 | 2021-10-06 | Illumina Inc | Multi-plane microarrays |
CA3016221C (en) | 2016-04-07 | 2021-09-28 | Illumina, Inc. | Methods and systems for construction of normalized nucleic acid libraries |
WO2017214561A1 (en) | 2016-06-10 | 2017-12-14 | Life Technologies Corporation | Methods and compositions for nucleic acid amplification |
WO2018018008A1 (en) | 2016-07-22 | 2018-01-25 | Oregon Health & Science University | Single cell whole genome libraries and combinatorial indexing methods of making thereof |
WO2018071522A1 (en) | 2016-10-11 | 2018-04-19 | Life Technologies Corporation | Rapid amplification of nucleic acids |
GB201704754D0 (en) | 2017-01-05 | 2017-05-10 | Illumina Inc | Kinetic exclusion amplification of nucleic acid libraries |
WO2018140540A1 (en) | 2017-01-25 | 2018-08-02 | Cue Health Inc. | Systems and methods for enhanced detection and quantification of analytes |
DK3615690T3 (en) | 2017-04-23 | 2021-11-15 | Illumina Cambridge Ltd | COMPOSITIONS AND METHODS FOR IMPROVING SAMPLE IDENTIFICATION IN INDEXED NUCLEIC ACID LIBRARIES |
EP3913053A1 (en) | 2017-04-23 | 2021-11-24 | Illumina Cambridge Limited | Compositions and methods for improving sample identification in indexed nucleic acid libraries |
ES2937929T3 (en) | 2017-04-23 | 2023-04-03 | Illumina Inc | Compositions and methods to improve sample identification in indexed nucleic acid libraries |
SG11201911730XA (en) | 2017-06-07 | 2020-01-30 | Univ Oregon Health & Science | Single cell whole genome libraries for methylation sequencing |
US11542540B2 (en) | 2017-06-16 | 2023-01-03 | Life Technologies Corporation | Control nucleic acids, and compositions, kits, and uses thereof |
WO2019002178A1 (en) | 2017-06-26 | 2019-01-03 | Thermo Fisher Scientific Baltics Uab | Thermophilic dna polymerase mutants |
EP3662482A1 (en) | 2017-07-31 | 2020-06-10 | Illumina Inc. | Sequencing system with multiplexed biological sample aggregation |
CN111566223B (en) | 2017-11-07 | 2024-04-12 | 生命技术公司 | Methods and compositions for manipulating nucleic acids |
AU2019248635B2 (en) | 2018-04-02 | 2022-01-27 | Illumina, Inc. | Compositions and methods for making controls for sequence-based genetic testing |
CA3067435C (en) | 2018-05-17 | 2023-09-12 | Illumina, Inc. | High-throughput single-cell sequencing with reduced amplification bias |
MX2019015262A (en) | 2018-06-04 | 2023-01-25 | Illumina Inc | High-throughput single-cell transcriptome libraries and methods of making and of using. |
AU2019402925A1 (en) | 2018-12-19 | 2021-01-14 | Illumina, Inc. | Methods for improving polynucleotide cluster clonality priority |
JP2022522917A (en) | 2019-03-01 | 2022-04-21 | イルミナ インコーポレイテッド | High-throughput single-nucleus and single-cell libraries, as well as manufacturing and usage |
EP3963103B1 (en) | 2019-05-03 | 2024-02-28 | Life Technologies Corporation | Methods and compositions for manipulating nucleic acids |
US11905558B2 (en) | 2019-08-21 | 2024-02-20 | Life Technologies Corporation | System and method for sequencing |
MX2021011847A (en) | 2019-12-19 | 2021-11-17 | Illumina Inc | High-throughput single-cell libraries and methods of making and of using. |
BR112022019541A2 (en) | 2020-03-30 | 2022-11-16 | Illumina Inc | METHODS AND COMPOSITIONS FOR PREPARING NUCLEIC ACID LIBRARIES |
CN115916967A (en) | 2020-05-12 | 2023-04-04 | 伊鲁米纳公司 | Production of nucleic acids having modified bases using recombinant terminal deoxynucleotidyl transferases |
WO2021252617A1 (en) | 2020-06-09 | 2021-12-16 | Illumina, Inc. | Methods for increasing yield of sequencing libraries |
JP2023532231A (en) | 2020-06-30 | 2023-07-27 | イルミナ インコーポレイテッド | Sequencing by Catalytically Controlled Synthesis to Generate Unblemished DNA |
US20220170093A1 (en) | 2020-11-16 | 2022-06-02 | Life Technologies Corporation | System and method for sequencing |
US20240117416A1 (en) | 2021-01-29 | 2024-04-11 | Illumina, Inc. | Methods, compositions and kits to improve seeding efficiency of flow cells with polynucleotides |
CN117222747A (en) | 2021-03-22 | 2023-12-12 | 伊鲁米纳剑桥有限公司 | Methods for improving clonality of nucleic acid clusters |
WO2023196572A1 (en) | 2022-04-07 | 2023-10-12 | Illumina Singapore Pte. Ltd. | Altered cytidine deaminases and methods of use |
NL2033124B1 (en) | 2022-09-23 | 2024-03-29 | Rapidemic B V | Methods and device for multiple-label nucleic acid amplification and detection |
WO2024069581A1 (en) | 2022-09-30 | 2024-04-04 | Illumina Singapore Pte. Ltd. | Helicase-cytidine deaminase complexes and methods of use |
WO2024073043A1 (en) | 2022-09-30 | 2024-04-04 | Illumina, Inc. | Methods of using cpg binding proteins in mapping modified cytosine nucleotides |
WO2024073047A1 (en) | 2022-09-30 | 2024-04-04 | Illumina, Inc. | Cytidine deaminases and methods of use in mapping modified cytosine nucleotides |
US20240209419A1 (en) | 2022-12-14 | 2024-06-27 | Illumina, Inc. | Systems and Methods for Capture and Enrichment of Clustered Beads on Flow Cell Substrates |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4713337A (en) * | 1985-01-03 | 1987-12-15 | Massachusetts Institute Of Technology | Method for deletion of a gene from a bacteria |
AU606043B2 (en) | 1985-03-28 | 1991-01-31 | F. Hoffmann-La Roche Ag | Detection of viruses by amplification and hybridization |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4888274A (en) * | 1985-09-18 | 1989-12-19 | Yale University | RecA nucleoprotein filament and methods |
JPS63109800A (en) | 1986-10-27 | 1988-05-14 | Rikagaku Kenkyusho | Determination of dna base sequence |
EP0322311B1 (en) | 1987-12-21 | 1994-03-23 | Applied Biosystems, Inc. | Method and kit for detecting a nucleic acid sequence |
-
1990
- 1990-05-07 US US07/520,321 patent/US5223414A/en not_active Expired - Fee Related
-
1991
- 1991-04-17 WO PCT/US1991/002626 patent/WO1991017267A1/en active IP Right Grant
- 1991-04-17 EP EP91910088A patent/EP0481065B1/en not_active Expired - Lifetime
- 1991-04-17 CA CA002056983A patent/CA2056983C/en not_active Expired - Fee Related
- 1991-04-17 JP JP3509357A patent/JP3010738B2/en not_active Expired - Fee Related
- 1991-04-17 DE DE69122712T patent/DE69122712T2/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
See references of WO9117267A1 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5994076A (en) * | 1997-05-21 | 1999-11-30 | Clontech Laboratories, Inc. | Methods of assaying differential expression |
US6489455B2 (en) | 1997-05-21 | 2002-12-03 | Clontech Laboratories, Inc. | Methods of assaying differential expression |
WO2006081583A2 (en) * | 2005-01-28 | 2006-08-03 | Helicos Biosciences Corporation | Methods and compositions for improving fidelity in a nucleic acid synthesis reaction |
WO2006081583A3 (en) * | 2005-01-28 | 2006-10-19 | Helicos Biosciences Corp | Methods and compositions for improving fidelity in a nucleic acid synthesis reaction |
Also Published As
Publication number | Publication date |
---|---|
DE69122712D1 (en) | 1996-11-21 |
JP3010738B2 (en) | 2000-02-21 |
WO1991017267A1 (en) | 1991-11-14 |
EP0481065B1 (en) | 1996-10-16 |
CA2056983C (en) | 2003-07-01 |
US5223414A (en) | 1993-06-29 |
CA2056983A1 (en) | 1991-11-08 |
DE69122712T2 (en) | 1997-02-20 |
JPH04507198A (en) | 1992-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5223414A (en) | Process for nucleic acid hybridization and amplification | |
US6361940B1 (en) | Compositions and methods for enhancing hybridization and priming specificity | |
Zoller et al. | [32] Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors | |
JP2546576B2 (en) | Nucleic acid sequence cloning method | |
JP2622327B2 (en) | Nucleic acid sequence amplification means | |
EP0702728B1 (en) | Magnetic cycle reaction | |
US6238866B1 (en) | Detector for nucleic acid typing and methods of using the same | |
JP3514630B2 (en) | Amplification and detection of nucleic acid sequences | |
EP0760002B1 (en) | Detection of mutation by resolvase cleavage | |
EP1712618B1 (en) | Method of amplifying nucleic acid and method of detecting mutated nucleic acid using the same | |
CN118291584A (en) | Nuclease-based RNA depletion | |
CN110719957B (en) | Methods and kits for targeted enrichment of nucleic acids | |
KR20010012175A (en) | Two-step hybridization and capture of a polynucleotide | |
WO1993014217A1 (en) | Use of predetermined nucleotides having altered base pairing characteristics in the amplification of nucleic acid molecules | |
WO1999036571A2 (en) | Method for the detection or nucleic acid of nucleic acid sequences | |
JPH0467960B2 (en) | ||
WO2009049630A1 (en) | Isothermal amplification method for detection of nucleic acid mutation | |
EP0358737A4 (en) | Genomic amplification with direct sequencing | |
JP2002514909A (en) | Compositions and methods for enhancing hybridization specificity | |
EP0509089A1 (en) | Compositions and methods for analyzing genomic variation | |
CN102424833A (en) | Real-time PCR gene detection chip for multiple gene mutation sites and detection method thereof | |
CN111808977B (en) | Design method and detection method of specific primers of resistance genes of rifampicin antibiotics caused by SNP | |
JPH0767646A (en) | Method for amplifying nucleic acid sequence using specific rna sequence contained in sample as template | |
JP4453115B2 (en) | Method for preparing labeled DNA | |
CN113454235A (en) | Improved nucleic acid target enrichment and related methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19911129 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): DE FR GB IT NL |
|
17Q | First examination report despatched |
Effective date: 19940405 |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: DAIKIN INDUSTRIES, LTD. |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): DE FR GB IT NL |
|
ET | Fr: translation filed | ||
REF | Corresponds to: |
Ref document number: 69122712 Country of ref document: DE Date of ref document: 19961121 |
|
ITF | It: translation for a ep patent filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20080312 Year of fee payment: 18 Ref country code: DE Payment date: 20080424 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20080428 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20080415 Year of fee payment: 18 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20080423 Year of fee payment: 18 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20090417 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20091101 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20091231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091103 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091101 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090417 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091222 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090417 |